$VXRT
Vaxart, Inc. Stock $vxrt

$vxrt Overview Financials Valuation SEC Filings Company Website

2016 Q2 Form 10-K Financial Statement

#000143774916038645 Filed on September 13, 2016

Income Statement

Concept	2016 Q2	2016 Q1	2016
Revenue	$600.0K	$5.300M	$9.300M
YoY Change	-85.37%	-10.17%	-62.2%
Cost Of Revenue	$7.400M	$10.50M
YoY Change	-69.29%	118.75%
Gross Profit	-$6.800M	-$5.200M	$9.300M
YoY Change	-66.0%	-572.73%	-55.71%
Gross Profit Margin	-1133.33%	-98.11%	100.0%
Selling, General & Admin	$1.300M	$2.300M	$8.000M
YoY Change	8.33%	-28.13%	-14.89%
% of Gross Profit			86.02%
Research & Development	$5.800M	$8.500M	$26.30M
YoY Change	-76.03%	77.08%	32.83%
% of Gross Profit			282.8%
Depreciation & Amortization	$100.0K	$0.00	$100.0K
YoY Change		-100.0%	-90.91%
% of Gross Profit			1.08%
Operating Expenses	$7.200M	$8.500M	$26.30M
YoY Change	-70.12%	77.08%	32.83%
Operating Profit	-$14.00M	-$5.200M	-$25.20M
YoY Change	-68.25%	-572.73%	29.23%
Interest Expense	$0.00		-$100.0K
YoY Change			-101.47%
% of Operating Profit
Other Income/Expense, Net	-$300.0K		-$200.0K
YoY Change			-166.67%
Pretax Income	-$7.000M	-$5.200M	-$25.40M
YoY Change	-65.0%	-533.33%	32.29%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$7.100M	-$5.200M	-$25.40M
YoY Change	-64.32%	-533.33%	32.98%
Net Earnings / Revenue	-1183.33%	-98.11%	-273.12%
Basic Earnings Per Share	-$0.18	-$0.14	-$0.66
Diluted Earnings Per Share	-$0.18	-$0.14	-$0.66
COMMON SHARES
Basic Shares Outstanding		38.64M	38.64M
Diluted Shares Outstanding		38.64M	38.64M

Balance Sheet

Concept	2016 Q2	2016 Q1	2016
SHORT-TERM ASSETS
Cash & Short-Term Investments	$69.00M	$49.00M	$69.00M
YoY Change	19.79%	-33.33%	19.79%
Cash & Equivalents	$49.70M	$30.60M	$49.70M
Short-Term Investments	$19.30M	$18.40M	$19.30M
Other Short-Term Assets	$2.700M	$1.400M	$2.700M
YoY Change	350.0%	55.56%	350.0%
Inventory
Prepaid Expenses
Receivables	$700.0K	$10.10M	$700.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$72.40M	$60.50M	$72.40M
YoY Change	2.26%	-30.78%	2.26%
LONG-TERM ASSETS
Property, Plant & Equipment	$300.0K	$400.0K	$300.0K
YoY Change	50.0%	33.33%	50.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$0.00	$1.000M	$0.00
YoY Change	-100.0%	11.11%	-100.0%
Other Assets	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Total Long-Term Assets	$300.0K	$1.400M	$300.0K
YoY Change	-96.51%	0.0%	-96.51%
TOTAL ASSETS
Total Short-Term Assets	$72.40M	$60.50M	$72.40M
Total Long-Term Assets	$300.0K	$1.400M	$300.0K
Total Assets	$72.70M	$61.90M	$72.70M
YoY Change	-8.44%	-30.29%	-8.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.900M	$3.700M	$3.900M
YoY Change	105.26%	270.0%	105.26%
Accrued Expenses	$3.600M	$4.500M	$1.400M
YoY Change	-33.33%	0.0%	-62.16%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$400.0K	$500.0K	$400.0K
YoY Change	100.0%		100.0%
Total Short-Term Liabilities	$9.200M	$8.700M	$9.200M
YoY Change	2.22%	20.83%	2.22%
LONG-TERM LIABILITIES
Long-Term Debt	$300.0K	$300.0K	$300.0K
YoY Change	-62.5%		-62.5%
Other Long-Term Liabilities	$200.0K	$200.0K	$17.00M
YoY Change	100.0%	100.0%	16900.0%
Total Long-Term Liabilities	$200.0K	$200.0K	$17.30M
YoY Change	100.0%	100.0%	1822.22%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.200M	$8.700M	$9.200M
Total Long-Term Liabilities	$200.0K	$200.0K	$17.30M
Total Liabilities	$26.50M	$9.200M	$26.50M
YoY Change	167.68%	26.03%	167.68%
SHAREHOLDERS EQUITY
Retained Earnings	-$134.3M	-$127.3M
YoY Change	23.32%	43.03%
Common Stock	$161.5M	$161.1M
YoY Change	1.25%	6.34%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$46.20M	$52.70M	$46.20M
YoY Change
Total Liabilities & Shareholders Equity	$72.70M	$61.90M	$72.70M
YoY Change	-8.44%	-30.29%	-8.44%

Cashflow Statement

Concept	2016 Q2	2016 Q1	2016
OPERATING ACTIVITIES
Net Income	-$7.100M	-$5.200M	-$25.40M
YoY Change	-64.32%	-533.33%	32.98%
Depreciation, Depletion And Amortization	$100.0K	$0.00	$100.0K
YoY Change		-100.0%	-90.91%
Cash From Operating Activities	$1.100M	-$7.000M	-$14.10M
YoY Change	450.0%	-975.0%	46.88%
INVESTING ACTIVITIES
Capital Expenditures	-$100.0K	-$100.0K	$200.0K
YoY Change		0.0%	100.0%
Acquisitions
YoY Change
Other Investing Activities	$100.0K	-$1.200M	$1.500M
YoY Change	-100.6%	-400.0%	-107.77%
Cash From Investing Activities	$0.00	-$1.300M	$1.300M
YoY Change	-100.0%	-533.33%	-106.7%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	18.00M	-100.0K	17.80M
YoY Change	-18100.0%		-17900.0%
NET CHANGE
Cash From Operating Activities	1.100M	-7.000M	-14.10M
Cash From Investing Activities	0.000	-1.300M	1.300M
Cash From Financing Activities	18.00M	-100.0K	17.80M
Net Change In Cash	19.10M	-8.400M	5.000M
YoY Change	-215.06%	-863.64%	-117.18%
FREE CASH FLOW
Cash From Operating Activities	$1.100M	-$7.000M	-$14.10M
Capital Expenditures	-$100.0K	-$100.0K	$200.0K
Free Cash Flow	$1.200M	-$6.900M	-$14.30M
YoY Change	500.0%	-866.67%	47.42%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2016	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2016	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2015Q2	avir	Deferred Tax Assets Sale Of Future Royalty Rights DeferredTaxAssetsSaleOfFutureRoyaltyRights
CY2015Q2	avir	Current Financial Assets CurrentFinancialAssets	70200000
CY2016Q2	avir	Current Financial Liabilities CurrentFinancialLiabilities	7900000
CY2015Q2	avir	Current Financial Liabilities CurrentFinancialLiabilities	8500000
CY2016Q2	avir	Deferred Tax Assets Accrued Compensated Related Costs DeferredTaxAssetsAccruedCompensatedRelatedCosts	1600000
CY2015Q2	avir	Accrued Research And Development Materials And Services AccruedResearchAndDevelopmentMaterialsAndServices	1700000
CY2016	avir	Available For Sale Securities Maturity Period AvailableForSaleSecuritiesMaturityPeriod	P1Y
CY2016Q2	avir	Current Financial Assets CurrentFinancialAssets	69700000
CY2016Q2	avir	Accrued Research And Development Materials And Services AccruedResearchAndDevelopmentMaterialsAndServices	2200000
CY2015Q2	avir	Deferred Tax Assets Accrued Compensated Related Costs DeferredTaxAssetsAccruedCompensatedRelatedCosts	1400000
CY2016Q2	avir	Deferred Tax Assets Amortization DeferredTaxAssetsAmortization	600000
CY2015Q2	avir	Deferred Tax Assets Amortization DeferredTaxAssetsAmortization	600000
CY2016Q2	avir	Deferred Tax Assets Depreciation DeferredTaxAssetsDepreciation
CY2015Q2	avir	Deferred Tax Assets Depreciation DeferredTaxAssetsDepreciation
CY2016Q2	avir	Deferred Tax Assets Sale Of Future Royalty Rights DeferredTaxAssetsSaleOfFutureRoyaltyRights	5400000
CY2016	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2016	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
CY2016	dei	Document Period End Date DocumentPeriodEndDate	2016-06-30
CY2016	dei	Document Type DocumentType	10-K
CY2015Q4	dei	Entity Public Float EntityPublicFloat	74200000
CY2016	dei	Trading Symbol TradingSymbol	avir
CY2016	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2016Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	38640487
CY2016	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2016	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2016	avir	Impairment Of Financial Assets ImpairmentOfFinancialAssets	0
CY2015	avir	Impairment Of Financial Assets ImpairmentOfFinancialAssets	0
CY2016	avir	Income Tax Rate Reconciliation Legal Ip Expense Amount IncomeTaxRateReconciliationLegalIPExpenseAmount
CY2015	avir	Income Tax Rate Reconciliation Legal Ip Expense Amount IncomeTaxRateReconciliationLegalIPExpenseAmount	6900000
CY2014	avir	Income Tax Rate Reconciliation Legal Ip Expense Amount IncomeTaxRateReconciliationLegalIPExpenseAmount
CY2016	avir	Income Tax Reconciliation Deferred Trueup Amount IncomeTaxReconciliationDeferredTrueupAmount	-900000
CY2015	avir	Income Tax Reconciliation Deferred Trueup Amount IncomeTaxReconciliationDeferredTrueupAmount
CY2014	avir	Income Tax Reconciliation Deferred Trueup Amount IncomeTaxReconciliationDeferredTrueupAmount
CY2016	avir	Income Tax Reconciliation Nondeductible Expense Research And Development Expense Benefit IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentExpenseBenefit
CY2015	avir	Income Tax Reconciliation Nondeductible Expense Research And Development Expense Benefit IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentExpenseBenefit
CY2014	avir	Income Tax Reconciliation Nondeductible Expense Research And Development Expense Benefit IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentExpenseBenefit	-100000
CY2016	avir	Increase Decrease Accrued Severance Obligations IncreaseDecreaseAccruedSeveranceObligations
CY2015	avir	Increase Decrease Accrued Severance Obligations IncreaseDecreaseAccruedSeveranceObligations	-2000000
CY2014	avir	Increase Decrease Accrued Severance Obligations IncreaseDecreaseAccruedSeveranceObligations	-1000000
CY2016Q2	avir	Net Financial Assets NetFinancialAssets	61800000
CY2015Q2	avir	Net Financial Assets NetFinancialAssets	61700000
CY2016	avir	Noncash Interest Expense On Liability NoncashInterestExpenseOnLiability	300000
CY2015	avir	Noncash Interest Expense On Liability NoncashInterestExpenseOnLiability
CY2014	avir	Noncash Interest Expense On Liability NoncashInterestExpenseOnLiability
CY2016	avir	Noncash Royalty Revenue Related To Sale Of Future Royalties NoncashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	200000
CY2015	avir	Noncash Royalty Revenue Related To Sale Of Future Royalties NoncashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
CY2014	avir	Noncash Royalty Revenue Related To Sale Of Future Royalties NoncashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
CY2016Q2	avir	Operating Leases Future Minimum Payments Due After Year Three OperatingLeasesFutureMinimumPaymentsDueAfterYearThree	500000
CY2016	avir	Proceeds From Sale Of Future Royalties Net ProceedsFromSaleOfFutureRoyaltiesNet	18100000
CY2015	avir	Proceeds From Sale Of Future Royalties Net ProceedsFromSaleOfFutureRoyaltiesNet
CY2014	avir	Proceeds From Sale Of Future Royalties Net ProceedsFromSaleOfFutureRoyaltiesNet
CY2016	dei	Amendment Flag AmendmentFlag	false
CY2016Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	7500000
CY2015Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	8300000
CY2016Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	3900000
CY2015Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1900000
CY2016Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	700000
CY2015Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	12600000
CY2016Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3600000
CY2015Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5400000
CY2016Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	100000
CY2015Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	800000
CY2016Q2	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent
CY2015Q2	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	500000
CY2016Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	300000
CY2015Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	200000
CY2016Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	19000000
CY2015Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	18900000
CY2016Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	157600000
CY2015Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	155600000
CY2014	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1400000
CY2015	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2100000
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2000000
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4751423
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3604737
CY2014	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2275441
CY2016Q2	us-gaap	Assets Assets	72700000
CY2015Q2	us-gaap	Assets Assets	79400000
CY2016Q2	us-gaap	Assets Current AssetsCurrent	72400000
CY2015Q2	us-gaap	Assets Current AssetsCurrent	70800000
CY2016Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	300000
CY2015Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	8600000
CY2016Q2	us-gaap	Available For Sale Securities AvailableForSaleSecurities	20800000
CY2015Q2	us-gaap	Available For Sale Securities AvailableForSaleSecurities	27100000
CY2016Q2	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	100000
CY2015Q2	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
CY2016Q2	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
CY2016Q2	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	20700000
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	81700000
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	66800000
CY2015Q2	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	100000
CY2015Q2	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	27200000
CY2016Q2	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	20800000
CY2015Q2	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	27100000
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	49700000
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	44700000
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	5000000
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-29100000
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	13400000
CY2016Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2015Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2016Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.10
CY2015Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.10
CY2016Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2015Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2016Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38640487
CY2015Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38609086
CY2016Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	38640487
CY2015Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	38609086
CY2016Q2	us-gaap	Common Stock Value CommonStockValue	3900000
CY2015Q2	us-gaap	Common Stock Value CommonStockValue	3900000
CY2014	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9500000
CY2015	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-27000000
CY2016	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-25300000
CY2016	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Concentration of Credit Risk and Other Risks and Uncertainties</div></div></div></div><div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Cash, cash equivalents and short- and long-term investments consist of financial instruments that potentially subject the Company to concentrations of credit risk to the extent recorded on the balance sheets. The Company believes that it has established guidelines for investment of its excess cash that maintain principal and liquidity through its policies on concentration, diversification, investment maturity, and investment grade.</div></div></div></div></div></div></div></div></div>
CY2016Q2	us-gaap	Cost Of Revenue CostOfRevenue	7400000
CY2016Q1	us-gaap	Cost Of Revenue CostOfRevenue	10500000
CY2015Q4	us-gaap	Cost Of Revenue CostOfRevenue	8200000
CY2015Q3	us-gaap	Cost Of Revenue CostOfRevenue	8400000
CY2015Q2	us-gaap	Cost Of Revenue CostOfRevenue	24100000
CY2015Q1	us-gaap	Cost Of Revenue CostOfRevenue	4800000
CY2014Q4	us-gaap	Cost Of Revenue CostOfRevenue	7500000
CY2014Q3	us-gaap	Cost Of Revenue CostOfRevenue	7700000
CY2016	us-gaap	Cost Of Services CostOfServices
CY2015	us-gaap	Cost Of Services CostOfServices	3600000
CY2014	us-gaap	Cost Of Services CostOfServices	51100000
CY2016	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit
CY2015	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit
CY2014	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit
CY2016	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit
CY2015	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	-100000
CY2014	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	-300000
CY2016	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit
CY2015	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-100000
CY2014	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-300000
CY2016	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit
CY2015	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit
CY2014	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit
CY2016	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit
CY2015	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit
CY2014	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit
CY2016	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit
CY2015	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit
CY2014	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit
CY2016Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1300000
CY2015Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent
CY2016Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	16800000
CY2015Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent
CY2016	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit
CY2015	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit
CY2014	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit
CY2016Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	36200000
CY2015Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	27600000
CY2016Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet
CY2015Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet
CY2016Q2	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent
CY2015Q2	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	500000
CY2016Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet
CY2015Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	500000
CY2016Q2	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent
CY2015Q2	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	500000
CY2016Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	6100000
CY2015Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	5400000
CY2016Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	20200000
CY2015Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	19800000
CY2016Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	100000
CY2015Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	400000
CY2016Q2	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	2200000
CY2015Q2	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch
CY2016Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	36200000
CY2015Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	27100000
CY2016Q2	us-gaap	Deferred Tax Liabilities Current DeferredTaxLiabilitiesCurrent
CY2015Q2	us-gaap	Deferred Tax Liabilities Current DeferredTaxLiabilitiesCurrent	500000
CY2016	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	200000
CY2015	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	400000
CY2014	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	800000
CY2016	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.04
CY2016	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	100000
CY2015	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1100000
CY2014	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2400000
CY2016Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
CY2016Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
CY2015Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2015Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2015Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.55
CY2015Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
CY2014Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.19
CY2014Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.20
CY2016	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.66
CY2015	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.54
CY2014	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.35
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.66
CY2015	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.54
CY2014	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.35
CY2016Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.18
CY2016Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
CY2015Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2015Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2015Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.55
CY2015Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
CY2014Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.19
CY2014Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.20
CY2016	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.66
CY2015	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.54
CY2014	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.35
CY2016	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents
CY2015	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-7900000
CY2014	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	1500000
CY2016Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	600000
CY2015Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1600000
CY2016	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	0
CY2015	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	0
CY2016Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	2600000
CY2015Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	3200000
CY2016	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y
CY2016	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0
CY2015	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0
CY2016	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-200000
CY2015	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	6500000
CY2014	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-1400000
CY2016	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1
CY2015	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-200000
CY2014	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1
CY2016	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	0
CY2016	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8000000
CY2015	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9400000
CY2014	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10200000
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-4900000
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-26700000
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-8300000
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-25400000
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-19200000
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11300000
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-20500000
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	7500000
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-3000000
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-100000
CY2014	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-300000
CY2016	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	9400000
CY2015	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	800000
CY2014	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4100000
CY2016	us-gaap	Income Tax Reconciliation Deductions Other IncomeTaxReconciliationDeductionsOther
CY2015	us-gaap	Income Tax Reconciliation Deductions Other IncomeTaxReconciliationDeductionsOther	-400000
CY2014	us-gaap	Income Tax Reconciliation Deductions Other IncomeTaxReconciliationDeductionsOther	-100000
CY2016	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	1000000
CY2015	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-400000
CY2014	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	400000
CY2016	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-8900000
CY2015	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-6700000
CY2014	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-4000000
CY2016	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	300000
CY2015	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
CY2014	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
CY2016	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-500000
CY2015	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	200000
CY2014	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-200000
CY2016	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-200000
CY2015Q2	us-gaap	Long Term Investments LongTermInvestments	7900000
CY2015	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1000000
CY2014	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-300000
CY2016	us-gaap	Income Tax Reconciliation Tax Credits Foreign IncomeTaxReconciliationTaxCreditsForeign	200000
CY2015	us-gaap	Income Tax Reconciliation Tax Credits Foreign IncomeTaxReconciliationTaxCreditsForeign	200000
CY2014	us-gaap	Income Tax Reconciliation Tax Credits Foreign IncomeTaxReconciliationTaxCreditsForeign
CY2016	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch
CY2015	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	100000
CY2014	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	300000
CY2016	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-700000
CY2015	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-15800000
CY2014	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	10600000
CY2016	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-11900000
CY2015	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-6200000
CY2014	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	7100000
CY2016	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue
CY2015	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue
CY2014	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-300000
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2100000
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-100000
CY2014	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1400000
CY2016	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	200000
CY2015	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	700000
CY2014	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	700000
CY2016Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	300000
CY2015Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	200000
CY2016Q2	us-gaap	Liabilities Liabilities	26500000
CY2015Q2	us-gaap	Liabilities Liabilities	9900000
CY2016Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	72700000
CY2015Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	79400000
CY2016Q2	us-gaap	Liabilities Current LiabilitiesCurrent	9200000
CY2015Q2	us-gaap	Liabilities Current LiabilitiesCurrent	9000000
CY2016Q2	us-gaap	Long Term Investments LongTermInvestments
CY2016Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	300000
CY2015Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	800000
CY2016	us-gaap	Nature Of Operations NatureOfOperations	<div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="WIDTH: 27pt; VERTICAL-ALIGN: top"> <div style=""><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">(1)</div></div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=""><div style="display: inline; font-weight: bold;"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Company Overview </div></div></div></div></td> </tr> </table> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Aviragen Therapeutics, Inc., together with its wholly owned subsidiaries (“Aviragen”, or the “Company”) is a biopharmaceutical company focused on the discovery and development of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has three product candidates in active clinical development: vapendavir, an oral treatment for human rhinovirus (“HRV”) upper respiratory infections in moderate-to-severe asthmatics currently being evaluated in the Phase 2b SPIRITUS trial; BTA585, an oral fusion protein inhibitor that has received Fast Track designation by the U.S. Food and Drug Administration (“FDA”), in Phase 2 development for the treatment and prevention of respiratory syncytial virus (“RSV”) infections; and BTA074, a topical antiviral treatment in Phase 2 development for condyloma caused by human papillomavirus types 6 and 11. The Company is incorporated in the state of Delaware and its corporate headquarters are located in Alpharetta, Georgia.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Although several of the Company’s influenza product candidates have been successfully developed and commercialized to-date by other larger pharmaceutical companies under collaboration, license or commercialization agreements with the Company, it has not independently developed or received regulatory approval for any product candidate, and the Company does not currently have any sales, marketing or commercial capabilities. Therefore, it is possible that the Company may not successfully derive any significant product revenues from any product candidates that it is developing now, or may develop in the future. The Company expects to incur losses for the foreseeable future as it intends to support the clinical and preclinical development of its product candidates. </div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company plans to continue to finance its operations with (i) existing cash, cash equivalents and investments, (ii) proceeds from existing or potential future royalty-bearing licenses or collaborative research and development arrangements, (iii) future equity and/or asset or debt financings, or (iv) other financing arrangements. The Company’s ability to continue to support its operations is dependent, in the near-term, upon managing its cash resources, continuing to receive royalty revenue under existing licenses, entering into future collaboration, license or commercialization agreements, the successful development of its product candidates, executing future financings and ultimately, upon the approval of its products for sale and achieving positive cash flows from operations on a consistent basis. There can be no assurance that additional capital or funds will be available on terms acceptable to the Company, if at all, that the Company will be able to enter into collaboration, license or commercialization agreements in the future, or that the Company will ever generate significant product revenue and become operationally profitable on a consistent basis.</div></div></div>
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	17800000
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-100000
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	26800000
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	1300000
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-19400000
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-10100000
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-14100000
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-9600000
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-3300000
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-11000000
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-19100000
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-25400000
CY2016Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.10
CY2014	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	80200000
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-25200000
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-19500000
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-11500000
CY2016Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	1400000
CY2016Q2	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	300000
CY2016Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	300000
CY2016Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	300000
CY2016Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	700000
CY2015Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1300000
CY2014	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1500000
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-7100000
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-5200000
CY2015Q4	us-gaap	Net Income Loss NetIncomeLoss	-6500000
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-6600000
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-19900000
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	1200000
CY2014Q4	us-gaap	Net Income Loss NetIncomeLoss	6500000
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-6900000
CY2016	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
CY2015	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	7500000
CY2014	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
CY2016	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-200000
CY2015	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	300000
CY2014	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	200000
CY2016Q2	us-gaap	Notes Payable Current NotesPayableCurrent	400000
CY2015Q2	us-gaap	Notes Payable Current NotesPayableCurrent	200000
CY2016	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	34500000
CY2015	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	44100000
CY2015	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-7800000
CY2016	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
CY2016Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	200000
CY2015Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	100000
CY2016	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	100000
CY2015	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	300000
CY2014	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	200000
CY2016	us-gaap	Other Operating Income OtherOperatingIncome
CY2015	us-gaap	Other Operating Income OtherOperatingIncome	100000
CY2014	us-gaap	Other Operating Income OtherOperatingIncome	100000
CY2016	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired
CY2015	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	8900000
CY2014	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired
CY2016	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	15300000
CY2015	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	17700000
CY2014	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	10000000
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	200000
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	100000
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	100000
CY2015Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2014	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess
CY2015	us-gaap	Proceeds From Sale Of Longterm Investments ProceedsFromSaleOfLongtermInvestments
CY2016Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	600000
CY2015Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	400000
CY2016Q2	us-gaap	Property Plant And Equipment Gross Excluding Capital Leased Assets PropertyPlantAndEquipmentGrossExcludingCapitalLeasedAssets	300000
CY2015Q2	us-gaap	Property Plant And Equipment Gross Excluding Capital Leased Assets PropertyPlantAndEquipmentGrossExcludingCapitalLeasedAssets	200000
CY2016Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	300000
CY2015Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	200000
CY2014	us-gaap	Proceeds From Sale Of Longterm Investments ProceedsFromSaleOfLongtermInvestments
CY2016	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment
CY2015	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	400000
CY2014	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment
CY2014	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	53500000
CY2015Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.10
CY2016Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2016Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2015Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2016Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2015Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2016Q2	us-gaap	Preferred Stock Value PreferredStockValue
CY2015Q2	us-gaap	Preferred Stock Value PreferredStockValue
CY2016Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2700000
CY2015Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	600000
CY2016	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock
CY2015	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock
CY2014	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	26800000
CY2016	us-gaap	Proceeds From Maturities Prepayments And Calls Of Longterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfLongtermInvestments
CY2015	us-gaap	Proceeds From Maturities Prepayments And Calls Of Longterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfLongtermInvestments	6900000
CY2014	us-gaap	Proceeds From Maturities Prepayments And Calls Of Longterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfLongtermInvestments
CY2016	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	16100000
CY2015	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
CY2014	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
CY2016	us-gaap	Proceeds From Sale Of Longterm Investments ProceedsFromSaleOfLongtermInvestments	700000
CY2016	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess
CY2015	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	17600000
CY2016	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	300000
CY2015	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	100000
CY2014	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	26300000
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19800000
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17500000
CY2016Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-134300000
CY2015Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-108900000
CY2016	us-gaap	Revenue Recognition Deferred Revenue RevenueRecognitionDeferredRevenue	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Non-Cash Interest Expense on Liability Related to Sale of Future Royalties </div></div></div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"> </div></div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In April 2016, the Company sold certain royalty rights related to the approved product Inavir®, sold by Daiichi Sankyo in the Japanese market, for $20 million to HealthCare Royalty Partners III, L.P. (“HCRP”). Under the relevant accounting guidance, due to a limit on the amount of royalties that HCRP can earn under the arrangement, this transaction was accounted for as a liability that will be amortized using the interest method over the life of the arrangement. The Company has no obligation to pay any amounts to HCRP other than to pass through to HCRP its share of royalties as they are received from Daiichi Sankyo. In order to record the amortization of the liability, the Company is required to estimate the total amount of future royalty payments to be received under the License Agreement and the payments that will be passed through to HCRP over the life of the agreement. The sum of the pass through amounts less the net proceeds received will be recorded as non-cash interest expense over the life of the liability. Consequently, the Company imputes interest on the unamortized portion of the liability and records non-cash interest expense using an estimated effective interest rate. The Company will periodically assess the expected royalty payments, and to the extent such payments are greater or less than the initial estimate, it will adjust the amortization of the liability and interest rate</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">.</div></div></div></div></div></div></div>
CY2016	us-gaap	Revenues Revenues	9300000
CY2015	us-gaap	Revenues Revenues	24600000
CY2014	us-gaap	Revenues Revenues	68700000
CY2016Q2	us-gaap	Revenues Revenues	600000
CY2016Q1	us-gaap	Revenues Revenues	5300000
CY2015Q4	us-gaap	Revenues Revenues	1700000
CY2015Q3	us-gaap	Revenues Revenues	1700000
CY2015Q2	us-gaap	Revenues Revenues	4100000
CY2015Q1	us-gaap	Revenues Revenues	5900000
CY2014Q4	us-gaap	Revenues Revenues	13900000
CY2014Q3	us-gaap	Revenues Revenues	700000
CY2016	us-gaap	Royalty Revenue RoyaltyRevenue	9100000
CY2015	us-gaap	Royalty Revenue RoyaltyRevenue	16100000
CY2014	us-gaap	Royalty Revenue RoyaltyRevenue	15100000
CY2016	us-gaap	Sales Revenue Services Gross SalesRevenueServicesGross
CY2015	us-gaap	Sales Revenue Services Gross SalesRevenueServicesGross	8400000
CY2014	us-gaap	Sales Revenue Services Gross SalesRevenueServicesGross	53600000
CY2016	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet
CY2015	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	8400000
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	3.93
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	3.93
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	1700000
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	3.93
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	2100000
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	2000000
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.014
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.017
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.015
CY2014	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	200000
CY2013Q2	us-gaap	Stockholders Equity StockholdersEquity	68000000
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.0075
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.0082
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.0079
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	8750
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	8750
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	8750
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	531252
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	249361
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	13.37
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	12.77
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1432000
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1636667
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.26
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.65
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.47
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2463369
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3364117
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4751423
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.09
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.58
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.07
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.42
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.17
CY2016Q2	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	2079033
CY2016Q2	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	4751423
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y292D
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y328D
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y328D
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y328D
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y219D
CY2016Q2	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	6.22
CY2016Q2	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	4.07
CY2016	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P6Y229D
CY2016Q2	us-gaap	Short Term Investments ShortTermInvestments	19300000
CY2015Q2	us-gaap	Short Term Investments ShortTermInvestments	12900000
CY2015	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised
CY2016	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised
CY2014	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	26800000
CY2015	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	7500000
CY2014Q2	us-gaap	Stockholders Equity StockholdersEquity	86900000
CY2015Q2	us-gaap	Stockholders Equity StockholdersEquity	69500000
CY2016Q2	us-gaap	Stockholders Equity StockholdersEquity	46200000
CY2015	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-100000
CY2016	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	100000
CY2014	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments
CY2016Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2016	us-gaap	Use Of Estimates UseOfEstimates	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Use of Estimates</div></div></div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The preparation of the consolidated financial statements requires management of the Company to make a number of estimates and assumptions relating to the reported amount of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Significant items subject to such estimates and assumptions include accruals, liabilities and obligations, tangible assets and deferred income taxes. Actual results could differ from those estimates.</div></div></div></div></div></div></div>
CY2016	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38635452
CY2015	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	35360841
CY2014	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31347888
CY2016	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	38635452
CY2015	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	35360841
CY2014	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	31347888
CY2016	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38635452
CY2015	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	35360841
CY2014	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31347888

Files In Submission

Name	View Source	Status
0001437749-16-038645-index-headers.html	Edgar Link	pending
0001437749-16-038645-index.html	Edgar Link	pending
0001437749-16-038645.txt	Edgar Link	pending
0001437749-16-038645-xbrl.zip	Edgar Link	pending
a1.jpg	Edgar Link	pending
avir-20160630.xml	Edgar Link	completed
avir-20160630.xsd	Edgar Link	pending
avir-20160630_cal.xml	Edgar Link	unprocessable
avir-20160630_def.xml	Edgar Link	unprocessable
avir-20160630_lab.xml	Edgar Link	unprocessable
avir-20160630_pre.xml	Edgar Link	unprocessable
bota20160630_10k.htm	Edgar Link	pending
debt.jpg	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex23-1a.htm	Edgar Link	pending
ex3-1.htm	Edgar Link	pending
ex3-2.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
hrv.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VXRT
Vaxart, Inc. Stock $vxrt

2016 Q2 Form 10-K Financial Statement

#000143774916038645 Filed on September 13, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VXRT Vaxart, Inc. Stock $vxrt

2016 Q2 Form 10-K Financial Statement

#000143774916038645 Filed on September 13, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VXRT
Vaxart, Inc. Stock $vxrt